Semaglutide Weight Regain After Stopping
Semaglutide for Weight Loss
Two-Thirds Regained
In the STEP 1 trial extension, participants who stopped semaglutide 2.4 mg regained two-thirds of their prior weight loss within one year.
Wilding et al., Diabetes Obesity and Metabolism, 2022
Wilding et al., Diabetes Obesity and Metabolism, 2022
View as imagePeople who stop taking semaglutide regain weight. That finding is consistent across every controlled trial, every real-world database analysis, and every meta-analysis published to date. The STEP 1 trial extension showed participants regained two-thirds of their weight loss within one year of stopping semaglutide 2.4 mg.[1] A 2025 meta-analysis in eClinicalMedicine calculated a mean regain of 5.63 kg after GLP-1 receptor agonist discontinuation.[2]
This is not a failure of the drug. It is a reflection of how obesity works. Semaglutide suppresses appetite, slows gastric emptying, and alters reward signaling in the brain while it is active. Remove the drug, and the biological pressures that drove weight gain in the first place return. This article covers exactly what happens after discontinuation, how fast regain occurs, what predicts who regains more or less, and what the evidence says about maintaining losses. For the broader picture of semaglutide's weight loss efficacy, see Semaglutide for Weight Loss Without Diabetes: What the Research Says.
Key Takeaways
- The STEP 1 extension trial showed a mean weight loss of 17.3% over 68 weeks on semaglutide 2.4 mg; participants regained two-thirds of that loss (approximately 12% of initial body weight) within one year of stopping treatment and lifestyle intervention (Wilding et al., Diabetes Obesity and Metabolism, 2022)
- Tzang et al. (2025) conducted a systematic review and meta-analysis in eClinicalMedicine finding a mean weight regain of 5.63 kg after GLP-1 RA discontinuation, with cardiometabolic markers (HbA1c, blood pressure, lipids) also rebounding
- Rodriguez et al. (2025) found that among US adults prescribed semaglutide or tirzepatide for weight management, 38.5% discontinued within 12 months, and 23% reinitiated therapy after stopping (JAMA Network Open)
- Gasoyan et al. (2025) reported that after semaglutide or tirzepatide discontinuation, weight began increasing within 30 days; by 12 months off therapy, the majority of weight lost during treatment had returned
- Kolli et al. (2025) meta-analysis compared GLP-1 RAs to other anti-obesity medications and found that weight regain was not unique to GLP-1 drugs, occurring across all drug classes after discontinuation
- Wang et al. (2026) identified gut microbiome composition and bile acid profiles as potential predictors of who experiences more rapid post-semaglutide weight regain, opening a new research direction
The STEP 1 extension: the foundational regain data
The STEP 1 trial (NCT03548935) randomized 1,961 adults with BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) and without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo, both combined with lifestyle intervention. The original trial, published in the New England Journal of Medicine, reported mean weight loss of 14.9% with semaglutide versus 2.4% with placebo.[3]
The extension phase followed a subset of participants for an additional year after both semaglutide and the structured lifestyle intervention were stopped at week 68. Wilding et al. (2022) reported the results: from week 68 to week 120, the semaglutide group regained a mean of 11.6 percentage points of the 17.3% total weight loss achieved during treatment, leaving a net retained loss of approximately 5.6% from baseline. Weight regain was continuous throughout the off-treatment period, with no sign of plateauing at week 120.[1]
Cardiometabolic improvements followed a similar pattern. Waist circumference, blood pressure, lipid profiles, C-reactive protein, and HbA1c all improved during treatment and deteriorated after withdrawal, though they remained slightly better than pre-treatment levels at week 120. The authors concluded that these findings "confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health."
Two aspects of this extension are often overlooked. First, the lifestyle intervention was also discontinued at week 68, meaning participants lost both the pharmacological and behavioral support simultaneously. This design makes it impossible to separate the contribution of semaglutide withdrawal from the loss of structured lifestyle coaching. Second, the placebo group also regained weight after stopping the lifestyle intervention, though from a much smaller loss, suggesting that structured behavioral programs alone also require maintenance.
Meta-analyses: how much weight comes back across studies
Two major meta-analyses published in 2025 attempted to quantify GLP-1 RA weight regain across multiple trials.
Tzang et al. (2025) conducted a systematic review and meta-analysis published in eClinicalMedicine (The Lancet Discovery Science) that included data from multiple GLP-1 RA discontinuation studies. They found a pooled mean weight regain of 5.63 kg after discontinuation, with semaglutide and tirzepatide studies showing greater absolute regain than liraglutide studies (reflecting greater initial weight loss). Cardiometabolic markers including HbA1c, systolic blood pressure, and LDL cholesterol also rebounded, though generally not to pre-treatment levels.[2]
Kolli et al. (2025) published a second meta-analysis in Cureus comparing weight regain after discontinuation of GLP-1 RAs versus other anti-obesity medications. Their analysis found that weight regain was not unique to GLP-1 drugs. Patients who stopped phentermine-topiramate, naltrexone-bupropion, and orlistat also regained weight, suggesting that regain after discontinuation is a feature of obesity pharmacotherapy as a class, not a specific liability of semaglutide.[4]
Quarenghi et al. (2025) reviewed weight regain specifically after liraglutide, semaglutide, and tirzepatide interruption across randomized studies. They found that the magnitude of regain correlated with the magnitude of initial loss: drugs that produced more weight loss also saw more absolute weight regain, though the proportion regained (roughly 50-67% within one year) was similar across agents.[5]
Real-world discontinuation patterns
Clinical trial regain data comes from controlled settings with selected populations. Real-world evidence paints a messier picture.
Rodriguez et al. (2025) analyzed claims data for US adults prescribed semaglutide or tirzepatide for weight management, published in JAMA Network Open. They found that 38.5% discontinued within 12 months. Among those who stopped, 23% reinitiated therapy, many within 6 months. Reinitiation rates were higher among patients who had experienced greater weight loss before stopping, suggesting that regain itself drove the decision to restart.[6]
Gasoyan et al. (2025) published two studies on discontinuation outcomes. The first examined weight trajectories after stopping semaglutide or tirzepatide, finding that weight began increasing within 30 days of discontinuation. By 12 months, the majority of treatment-period weight loss had reversed.[7] The second study identified the most common reasons for discontinuation: cost/insurance issues (the dominant factor), side effects (primarily GI symptoms), and achieving a personal weight goal.[8]
Xu et al. (2025) examined commercial insurance claims and found that among patients prescribed semaglutide for weight management, discontinuation was highest during the dose escalation phase. Patients who achieved the target 2.4 mg dose were more likely to persist on treatment, suggesting that early tolerability determines long-term adherence as much as efficacy does.[9]
For more on the side effects that drive early discontinuation, see Nausea on Semaglutide or Tirzepatide: Why It Happens and How Long It Lasts.
Why regain happens: the biological argument
Weight regain after semaglutide discontinuation is not a matter of willpower. It reflects the reversal of multiple biological mechanisms that semaglutide engages.
Semaglutide acts on GLP-1 receptors in the hypothalamus, brainstem, and gut to reduce appetite, slow gastric emptying, and alter the reward value of food. When the drug is cleared (half-life approximately 7 days, functionally gone within 5-6 weeks of the last injection), these effects reverse. Appetite returns to pre-treatment levels. Gastric emptying normalizes. The hedonic response to calorie-dense foods reverts. For a detailed explanation of these mechanisms, see How Much Weight Can You Lose on Semaglutide? A Look at the Data.
Additionally, weight loss itself triggers compensatory metabolic responses. Resting metabolic rate decreases in proportion to lost body mass. Levels of the satiety hormone leptin fall, removing a brake on appetite. Levels of the hunger hormone ghrelin rise. These adaptations, which evolved to defend against starvation, do not distinguish between intentional weight loss and famine. They persist for months to years after weight loss, creating a biological drive to restore lost fat mass regardless of whether weight loss was achieved by diet, surgery, or pharmacotherapy.
Singh et al. (2025) reviewed obesity as a chronic disease, arguing that the expectation of sustained weight loss after stopping medication contradicts the disease model. They noted that no one expects blood pressure to remain controlled after stopping antihypertensives, and the same logic applies to obesity pharmacotherapy.[10]
Who regains more and who regains less
Not everyone regains at the same rate. Emerging research is identifying predictors.
Wang et al. (2026) published a study in Diabetes Obesity and Metabolism examining post-semaglutide weight regain in females with obesity. They found that gut microbiome composition and bile acid profiles measured at the time of discontinuation predicted the rate and magnitude of weight regain. Patients with greater microbial diversity and specific bile acid patterns regained less weight, suggesting that the gut ecosystem may partially buffer against regain.[11]
The Epic Research analysis of electronic health records found that more than half of patients maintained weight loss a year after stopping semaglutide or liraglutide, but 17.7% of semaglutide users regained all the weight they had lost or more. This heterogeneity matters: the average regain of "two-thirds" obscures a wide distribution from near-complete maintenance to overshoot.
Factors associated with greater regain in observational data include: shorter treatment duration, greater initial weight loss (paradoxically, those who lose the most also regain the most in absolute terms), lack of concurrent lifestyle changes, and younger age. Factors associated with better maintenance include: longer treatment duration before stopping, concurrent resistance training, higher protein intake, and gradual dose tapering rather than abrupt cessation.
Strategies studied for reducing regain
Reiss et al. (2025) reviewed paths for discontinuation while maintaining weight loss, evaluating evidence for several strategies.[12]
Gradual dose tapering: Some clinical protocols taper semaglutide doses over 8-12 weeks rather than stopping abruptly. The physiological rationale is that gradual withdrawal allows appetite regulation to readjust incrementally. One clinical series reported that weight remained stable during a 9-week taper with concurrent diet and exercise coaching, with average additional weight loss of 1.5% during 26 weeks after complete cessation. This is promising but uncontrolled data.
Transition to lower-cost maintenance: Pampanelli et al. (2026) studied flexible dosing of semaglutide, where patients who achieved their weight loss goal were maintained on lower doses (0.5-1.0 mg weekly instead of 2.4 mg). Early discontinuation rates were lower with flexible dosing, and comparable weight outcomes were maintained, suggesting that full-dose treatment may not be necessary for maintenance in all patients.[13]
Exercise as a buffer: Exercise does not prevent regain entirely, but it attenuates it. Resistance training preserves lean mass, which supports metabolic rate. Aerobic exercise improves insulin sensitivity independently of weight. The combination may slow the rate of regain by partially compensating for the metabolic adaptations that follow weight loss. For how semaglutide affects body composition specifically, see Does Semaglutide Change Your Body Composition? Fat Loss vs Muscle Loss.
Switching to a different agent: Mousavi et al. (2025) reviewed the role of GLP-1 RAs in treating weight regain after bariatric surgery, noting that some patients who regain after stopping one agent respond to reinitiation or to switching to a different GLP-1 RA or dual agonist.[14] Del Prete et al. (2025) found that in a real-world Italian cohort, maintenance on semaglutide after initial bariatric surgery preserved weight loss more effectively than discontinuation.[15]
The cost and access dimension
Regain data cannot be separated from the economics of GLP-1 RA treatment. Gasoyan et al. (2025) found that cost and insurance coverage were the leading reasons for discontinuation, not lack of efficacy or intolerable side effects.[8] If obesity is a chronic disease requiring ongoing treatment, then access to that treatment determines outcomes as much as pharmacology does.
Rodriguez et al. (2025) documented that among patients who discontinued, those with continuous insurance coverage were more likely to reinitiate than those who experienced coverage gaps. This creates a two-tier system: patients with stable insurance access can resume treatment when regain becomes unacceptable, while those without coverage experience the full trajectory of weight regain without a pharmacological option to reverse it.[6]
Ishiguro et al. (2026) analyzed discontinuation of oral semaglutide specifically and found that adverse GI effects were the primary driver of dropout for the oral formulation, a distinct pattern from injectable semaglutide where cost dominates.[16] For a comparison of oral versus injectable delivery, see Ozempic vs Wegovy: Same Drug, Different Purpose.
What the regain data means for the field
The weight regain data after semaglutide discontinuation has reshaped how obesity researchers and clinicians think about GLP-1 RA therapy. Three conclusions emerge from the evidence:
First, semaglutide is effective while active. The STEP program demonstrated reproducible, clinically meaningful weight loss across diverse populations. The drug works. The question has never been efficacy; it is durability after withdrawal.
Second, obesity behaves like other chronic conditions. Blood pressure rises after stopping antihypertensives. Blood glucose rises after stopping metformin. Weight rises after stopping semaglutide. The regain data is consistent with the American Medical Association's 2013 classification of obesity as a chronic disease requiring ongoing management.
Third, the research gap is in maintenance strategies. Fewer than 5 randomized controlled trials have studied what happens when patients transition off semaglutide with structured support versus abrupt discontinuation. The field has invested heavily in proving that GLP-1 RAs cause weight loss and relatively little in studying how to sustain that loss when treatment ends.
For context on how long semaglutide takes to reach full effect, see How Long Does It Take for Semaglutide to Work?.
The Bottom Line
Weight regain after stopping semaglutide is well-documented, consistent, and biologically expected. The STEP 1 extension showed two-thirds regain within a year. Multiple 2025 meta-analyses confirmed this pattern across GLP-1 RAs. Real-world data adds that cost is the primary driver of discontinuation, and that regain trajectories vary widely between individuals. Strategies like dose tapering, flexible maintenance dosing, and concurrent exercise show preliminary promise but lack robust trial evidence. The regain data supports treating obesity as a chronic condition requiring sustained intervention, not a short-term problem solvable with a finite course of medication.